Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adaptimmune Ther ADR (NQ: ADAP )

1.800 +0.030 (+1.69%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 258,151
Open 1.770
Bid (Size) 1.750 (8)
Ask (Size) 1.830 (20)
Prev. Close 1.770
Today's Range 1.750 - 1.860
52wk Range 1.010 - 3.315
Shares Outstanding 982,974,108
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Publication of Data from Adaptimmune's Completed Phase 1 Trial with Afami-cel in Nature Medicine Demonstrating an Acceptable Safety Profile and Encouraging Responses in Synovial Sarcoma
-The response rate was 44% in patients with late-stage, metastatic synovial sarcoma after a single dose of afami-cel --... 
Via Newsfile
Expert Ratings for Adaptimmune Therapeutics
 
Via Benzinga

Performance

YTD
+7.78%
+7.78%
1 Month
+44.00%
+44.00%
3 Month
+29.50%
+29.50%
6 Month
-2.70%
-2.70%
1 Year
-33.58%
-33.58%

More News

Read More
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Adaptimmune Announces Initiation of Biologics License Application (BLA) Submission for Afami-cel, Its First-Gen Engineered TCR T-cell Therapy targeting MAGE-A4, For the Treatment of Synovial Sarcoma
Via Newsfile
Exposures Product Safety
Credit Suisse, Autodesk And Other Big Losers From Wednesday
Via Benzinga
Why Adaptimmune Therapeutics Stock Is Glowing Green Today
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma - Response Rate and Durability Remain Consistent
Via Newsfile
Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Via Benzinga
Adaptimmune Reports Third-Quarter Financial Results and Business Update
Via Newsfile
Adaptimmune Reports Increased Response Rate and Durability of Response in Its Phase 1 SURPASS trial; ORR Now 52% Across Ovarian, Urothelial, and Head & Neck Cancers
Via Newsfile
Exposures Product Safety
Adaptimmune to Report Q3 2022 Financial and Business Updates on Tuesday, November 8, 2022
Via Newsfile
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
GSK Transfers Cell Therapy Program Rights To Adaptimmune, Terminates Second Cell Therapy Pact In A Day
Via Benzinga
Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK
Via Newsfile
Domino's Pizza To $385? Plus This Analyst Cuts Price Target On Adaptimmune Therapeutics By Around 79%
Via Benzinga
Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary
Via Benzinga
Adaptimmune's Cancer Candidate Shows 44% Response Rate In Pretreated Ovarian, Urothelial, Head & Neck Cancers
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
Via Newsfile
Adaptimmune to Host Live, Virtual Event to Review Phase 1 SURPASS Trial Data and Outline Plans for Further Development in SURPASS Family of Trials
Via Newsfile
Adaptimmune Therapeutics: Q2 Earnings Insights
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.